HC Wainwright & Co. Reiterates Buy on Annovis Bio, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Annovis Bio (NYSE:ANVS) and maintained a $30 price target.
March 21, 2024 | 10:22 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates a Buy rating on Annovis Bio with a $30 price target.
The reiteration of a Buy rating and maintenance of a $30 price target by a reputable analyst suggests a positive outlook on Annovis Bio's stock. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100